Actively Recruiting

Phase Not Applicable
Age: 18Years - 75Years
All Genders
NCT06778460

Effect of Esketamine and Lidocaine on Postoperative Chronic Pain and Long-term Survival in Patients Undergoing Hepatectomy

Led by West China Hospital · Updated on 2025-01-16

304

Participants Needed

1

Research Sites

203 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study is a further observation and follow-up of the patients enrolled in the registration number ChiCTR230007164430 to further evaluate the effect of long-term infusion of esketamine and lidocaine on postoperative chronic pain, long-term quality of life and survival rate in patients undergoing hepatectomy.

CONDITIONS

Official Title

Effect of Esketamine and Lidocaine on Postoperative Chronic Pain and Long-term Survival in Patients Undergoing Hepatectomy

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Aged 18-75 years
  • Scheduled for elective hepatectomy
  • ASA grade I-III
Not Eligible

You will not qualify if you...

  • Patients intubated in ICU after surgery without planned extubation within 6 hours postoperatively
  • Body weight under 40 kg or over 100 kg
  • Cardiac conduction abnormalities (second- or third-degree atrioventricular block) or cardiac insufficiency with left ventricular ejection fraction below 50%
  • Severe liver insufficiency with ALT, AST, or bilirubin levels more than 2.5 times the upper limit of normal
  • Renal insufficiency with creatinine clearance under 60 mL/min
  • Known allergy to esketamine or lidocaine
  • History of long-term opioid abuse
  • Unable to communicate effectively
  • Serious medical conditions like uncontrolled hypertension, coronary heart disease, intracranial vascular malformations, or acute asthma attacks
  • History of epilepsy or manic episodes
  • Pregnant or breastfeeding women
  • Glaucoma
  • Preoperative cognitive dysfunction, bipolar disorder, or other psychiatric disorders including mental retardation
  • Primary liver cancer with other malignant tumors or signs of distant metastasis

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

West China Hospital

Chengdu, Sichuan, China

Actively Recruiting

Loading map...

Research Team

C

Chunling Jiang, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here